CurrentUnitedHealthcarePolicy 2025D0063J

Trogarzo (ibalizumab-uiyk) — coverage criteria for multi-drug resistant HIV-1

Defines UnitedHealthcare medical necessity criteria and administrative requirements for coverage of Trogarzo (ibalizumab-uiyk) for treatment of multi-drug resistant HIV-1 in affected members. Applies to providers seeking authorization for initial and continuation therapy under UnitedHealthcare plans.

Policy Summary

PayerUnitedHealthcare

PolicyTrogarzo (ibalizumab-uiyk) — coverage criteria for multi-drug resistant HIV-1

Policy CodePolicy 2025D0063J

Change TypeNo material changes

Effective DateJun 1, 2025

Next Review DateN/A

Key ActionObtain prior authorization and document diagnosis, provider attestation of multi‑drug resistant HIV‑1, and an optimized background regimen with at least one fully susceptible agent.

SourceLink

J1746HCPCS

12 moInit auth ≤

12 moCont auth ≤

MDR HIV-1FDA indication

43%Trial response

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Initial Therapy Criteria

Covered when ALL of the following are met for initial therapy:

Initial therapy main

Diagnosis and attestation: Diagnosis of HIV-1 infection AND provider attestation that the patient has multi-drug resistant HIV-1 infection
Optimized background regimen: Provider confirms that the patient has been prescribed an optimized background antiretroviral regimen containing at least one antiretroviral agent that demonstrates full viral sensitivity/susceptibility
Dosing: Trogarzo (ibalizumab-uiyk) initial and maintenance dosing is in accordance with the US Food and Drug Administration prescribing information
Authorization duration: Initial authorization is for no more than 12 months

(operational note): Prior authorization is required; submit documentation of HIV-1 diagnosis, provider attestation of multidrug-resistant HIV-1, and the optimized background regimen; include relevant diagnosis and HCPCS codes (e.g., B20, Z16.33, Z21, J1746)

Continuation Therapy Criteria

Covered when ALL of the following are met for continuation therapy:

Continuation therapy main

Prior treatment: Patient has previously received treatment with Trogarzo (ibalizumab-uiyk)
Clinical response: Provider confirms the patient has achieved a clinically significant viral response to Trogarzo (ibalizumab-uiyk) therapy
Continued OBR: Provider confirms patient will continue an optimized background antiretroviral regimen in combination with Trogarzo (ibalizumab-uiyk)
Dosing and authorization: Trogarzo (ibalizumab-uiyk) maintenance dosing is in accordance with the US Food and Drug Administration prescribing information; authorization is for no more than 12 months

Use of ibalizumab (Trogarzo) is intended for heavily treatment‑experienced adults with multidrug‑resistant HIV‑1 who are failing their current antiretroviral regimen. The policy restricts coverage to this population and requires documentation that the member’s infection is not adequately controlled by standard regimens, consistent with the FDA indication and clinical trial populations studied. Coverage is conditional on provider attestation of multidrug resistance and confirmation of an optimized background regimen to accompany ibalizumab.

Per Department of Health and Human Services (DHHS) guidance and the product’s labeled indication, ibalizumab is not recommended as initial therapy when standard effective initial antiretroviral options exist. The agent is reserved for patients without sufficient treatment options to construct a fully suppressive regimen; policy requirements therefore limit use to heavily treatment‑experienced individuals with documented resistance to multiple antiretroviral classes.

Provider Actions — Authorization, Documentation, and Denial Triggers

Prior Authorization

Prior Authorization Required

Prior authorization is required for both initial and continuation therapy. Initial and continuation authorizations may be approved for up to 12 months when all coverage criteria are met. Providers should submit a prior authorization request that documents the clinical rationale and supports the attestation of multidrug-resistant (MDR) HIV-1.

Initial and continuation authorization duration: up to 12 months when criteria met
Submit prior authorization to UnitedHealthcare per standard processes

Step Therapy

Step Therapy / Sequencing

No routine step therapy sequence is mandated; Trogarzo is intended for heavily treatment‑experienced patients with multidrug‑resistant HIV‑1 who are failing their current regimen. Clinicians must confirm the patient is treatment‑experienced and that Trogarzo is being prescribed in the context of an optimized background antiretroviral regimen.

Policy applies to heavily treatment‑experienced patients with MDR HIV‑1
No prior requirement to trial other specific agents if patient meets MDR and OBR criteria

Documentation Required

Required Documentation

Providers must document the clinical evidence supporting use of Trogarzo. Required documentation includes diagnosis and clinical status, provider attestation of multidrug‑resistant HIV‑1, and confirmation of an optimized background antiretroviral regimen that contains at least one agent with full viral susceptibility. For continuation requests, include documentation of prior Trogarzo use and evidence of a clinically significant virologic response.

Diagnosis: HIV‑1 infection (e.g., B20)
Provider attestation: patient has multidrug‑resistant (MDR) HIV‑1
Optimized background regimen (OBR): documentation that OBR is prescribed and includes ≥1 agent with documented full susceptibility
Initial dosing and maintenance must follow FDA prescribing information
For continuation: documentation of prior Trogarzo treatment and clinically significant viral response

Denial Risk

Triggers for Denial

Authorization may be denied if required documentation or attestations are missing, or if the patient does not meet the policy criteria. Common triggers for denial include absence of provider attestation of MDR HIV‑1, lack of documentation showing an optimized background regimen with at least one fully susceptible agent, dosing inconsistent with FDA labeling, or no evidence of prior benefit when requesting continuation.

Missing provider attestation of multidrug‑resistant HIV‑1
No documentation of an optimized background antiretroviral regimen with ≥1 fully susceptible agent
Dosing not in accordance with FDA prescribing information
For continuation: no evidence of prior Trogarzo use or no documented clinically significant virologic response

Background — Drug Mechanism and Indication

Trogarzo (ibalizumab‑uiyk) is a CD4‑directed, post‑attachment HIV‑1 inhibitor — a humanized monoclonal antibody that binds to the CD4 receptor and blocks HIV‑1 entry into CD4+ cells. It is used in combination with other antiretroviral agents for treatment of heavily treatment‑experienced adults with multi‑drug resistant HIV‑1. In clinical studies patients received a single IV loading dose of 2000 mg followed by maintenance dosing of 800 mg IV every two weeks, and trial results demonstrated antiviral activity including reductions in viral load and increases in CD4+ T cell counts when given with an optimized background regimen.

Definitions — Key Terms

Multi-drug resistant HIV-1 — definition and clinical threshold/meaning

DefinitionHIV-1 infection in patients with resistance to multiple antiretroviral agents such that standard regimens are not fully suppressive; provider attestation of multi‑drug resistant (MDR) HIV‑1 is required for coverage.

Clinical meaning/thresholdApplies to heavily treatment‑experienced adults with multi‑drug resistant HIV‑1 who are failing their current antiretroviral regimen.

Therapeutic implicationPatients have HIV‑1 strains resistant to approved antiretroviral agents; Trogarzo (ibalizumab‑uiyk) is active against such resistant strains.

Regulatory contextFDA indicates use in combination with other antiretroviral(s) for heavily treatment‑experienced adults with multi‑drug resistant HIV‑1.

Clinical trial relevancePolicy references evidence from studies of ibalizumab plus an optimized background regimen in heavily treatment‑experienced patients with MDR HIV‑1.

Optimized background regimen (OBR) — definition and intended use

DefinitionAn optimized background regimen (OBR) is a combination antiretroviral regimen selected so that at least one agent demonstrates full viral sensitivity/susceptibility and is used in combination with ibalizumab as part of therapy for MDR HIV‑1.

Intended useOBR is used alongside Trogarzo (ibalizumab‑uiyk) to provide companion antiretroviral activity when treating heavily treatment‑experienced patients with multi‑drug resistant HIV‑1.

Coverage requirementProvider must confirm the patient has been prescribed an OBR containing at least one antiretroviral agent demonstrating full viral sensitivity/susceptibility for initial and continuation coverage criteria.

Clinical rationaleCombining ibalizumab with an OBR provides additional antiretroviral agents to which the virus may remain susceptible, supporting viral suppression in MDR cases.